Media about us

• Pfizer and NovaMedica complete strategic partnership

  28 December 2016 The Pharma Letter

  

  US pharma giant Pfizer (NYSE: PFE) and Russia’s NovaMedica, a company established in 2012 by Russian high-technology investment fund Rusnano and American healthcare fund Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio.

• US-Russia Relations: Why Donald Trump is Right to Look East

  19 December 2016 David Morgan / Global Research

  

  ​US President-elect Donald J Trump has been widely criticised by his liberal critics in the media and by Democratic Party opponents for wanting to normalise his country’s relations with Russia and to adopt a more balanced approach towards Moscow.

• Nurse to get newly improved cornea inlay to improve near vision

  07 December 2016 The Tennessean

  

  Diane McTaggart will be among the first Middle Tennesseans to undergo a newly approved device to treat loss of near vision associated with aging, also known as presbyopia. The U.S. Food and Drug Administration approved ReVision Optics' Raindrop Near Vision Inlay — a device that gets implanted in the cornea — this summer. The tiny inlay looks like a small contact lens, albeit smaller than a needle's eye, that is made out of hydrogel material. It's approved for people aged 41 to 65 who need reading glasses for small print but do not glasses for distance vision, and have not had cataract surgery.

• Minimally invasive surgical solutions for presbyopia

  28 November 2016 Jeffrey Whitman, MD / Optometry Times

  

  The three inlays have different designs and correct presbyopia via different mechanisms. Results from FDA studies for both the Kamra inlay and Raindrop Near Vision Inlay showed patients achieved very good near and intermediate uncorrected visual acuity. Maintenance of good uncorrected binocular distance vision is a feature of all of the corneal inlays.

• 5 Biotech IPOs Lead The Way In 2016

  25 November 2016 Don Dion / Seeking Alpha

  

  While the IPO market was relatively weak in 2016 overall, biopharma IPOs excelled. We have been particularly impressed with AveXis, Clearside Biomedical, Protagonist Therapeutics, Reata Pharma, and bluebird bio. We plan to initiate or build on existing long positions in these companies heading into 2017.

• Sun Pharma moves on Russia with deal for control of JSC Biosintez

  23 November 2016 Eric Palmer / Fierce Pharma

  

  India’s Sun Pharma is joining the growing number of companies snagging a portfolio and local manufacturing in Russia with a deal worth $60 million to buy control of a Russian drug producer. Pfizer last summer announced its third deal in Russia to establish local manufacturing. It and Russia’s NovaMedica are building a manufacturing plant in the Kaluga region which they say will be producing drugs by 2020. 

• Corneal Inlays Better Than Monovision, Researchers Say

  28 October 2016 Marcia Frellick / MedScape

  

  One of the biggest misperceptions about corneal inlays is that the end result is monovision, experts said here at the American Academy of Ophthalmology (AAO) 2016 Annual Meeting. This is not true, according to Greg Parkhurst, MD, chief executive officer of Parkhurst NuVision in San Antonio, Texas, who is a principal investigator on clinical trials of the Raindrop Near Vision Inlay (ReVision Optics).

• Chairman highlights 2016 industry highlights at OIS

  19 October 2016 Healio

  

  The past year has seen a number of important approvals and promising study progress in both biotechnology and ophthalmic devices, Emmett T. Cunningham Jr., MD, PhD, MPH, told the more than 900 attendees at the Ophthalmology Innovation Summit in his “Chairman’s 2016 Year in Review.”

• Liquid biopsy open database created under Cancer Moonshot, as pharma joins the fray

  19 October 2016 Stacy Lawrence / Fierce Biotech

  

  Twenty stakeholders, including major biopharmas, diagnostic players and academic institutions, have committed to creating what they expect will be the largest liquid biopsy open database for cancer genomic profiling data. It’s part of the broader ongoing Cancer Moonshot effort led by U.S. Vice President Joe Biden.

• White House To Announce Big Push For Cancer Blood Tests

  19 October 2016 Matthew Herper / Forbes

  

  The White House, as part of the Cancer Moonshot effort being run by Vice President Joe Biden, is announcing a major push to develop blood tests that can detect and monitor cancer, that aims to unite makers of diagnostic tests, drugs, and other cancer-related products.